STOXX Europe 600 Index Ends 0.56% Lower at 514.81 — Data Talk
The STOXX Europe 600 Index is down 2.89 points or 0.56% today to 514.81
--Down for two consecutive trading days
--Down 4.06 points or 0.78% over the last two trading days
--Largest two day point and percentage decline since Monday, June 17, 2024
--Down three of the past four trading days
--Off 1.89% from its record close of 524.71 hit Wednesday, May 15, 2024
--Lowest closing value since Wednesday, June 19, 2024
--Off 1.89% from its 52-week high of 524.71 hit Wednesday, May 15, 2024
--Up 19.84% from its 52-week low of 429.58 hit Friday, Oct. 27, 2023
--Rose 12.89% from 52 weeks ago
--Off 1.89% from its 2024 closing high of 524.71 hit Wednesday, May 15, 2024
--Up 10.07% from its 2024 closing low of 467.71 hit Wednesday, Jan. 17, 2024
--Month-to-date it is down 0.65%
--Year-to-date it is up 35.82 points or 7.48%
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
June 26, 2024 12:36 ET (16:36 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks